Grifols Class A/€GRF

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About Grifols Class A

Grifols SA, operating under the ticker GRF, is a biopharmaceutical company specialized in the production of plasma-derived medicines. Founded in 1940 and headquartered in Barcelona, Spain, Grifols is engaged in the diagnosis, prevention, and treatment of a variety of diseases, with a strong focus on immunology, hematology, and intensive care sectors. The company operates globally, leveraging advanced technologies and rigorous quality processes to provide essential medical products.

Ticker

€GRF

Primary listing

BME

Industry

Biotechnology
Headquarters

Employees

23,800

ISIN

ES0171996087

Grifols Class A Metrics

BasicAdvanced
€6.1B
34.78
€0.29
0.93
-

What the Analysts think about Grifols Class A

Analyst ratings (Buy, Hold, Sell) for Grifols Class A stock.

Bulls say / Bears say

Grifols reported a 179% year-over-year increase in net profit for Q1 2025, reaching €60 million, driven by a 7.4% rise in net revenue to €1.79 billion, primarily from its plasma-derived medicine business. (reuters.com)
Moody's upgraded Grifols' credit rating from B3 to B2 with a positive outlook, recognizing the company's improved financial health and liquidity, which could facilitate the resumption of dividend payments. (cincodias.elpais.com)
Grifols' shares rose by 4.4% following reports that Canadian fund Brookfield is considering a new takeover attempt, indicating strong investor interest and potential for increased shareholder value. (investing.com)
A U.S. Federal District Court ruled that Grifols' defamation lawsuit against Gotham City Research can proceed, stemming from allegations of financial misconduct that previously led to a significant loss in market value. (reuters.com)
Grifols' debt-to-equity ratio stands at 104.3%, with total debt of €9.0 billion, indicating a high level of leverage that could pose financial risks. (simplywall.st)
The company's net profit margin is relatively low at 3.49%, which may raise concerns about profitability and operational efficiency. (google.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.

Grifols Class A Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Grifols Class A Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €GRF

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs